
Eli Lilly
Eli Lilly in Fortune Rankings
- About
- Great Place to Work
- Earnings Reports
Eli Lilly is the powerhouse behind today’s blockbuster drugs Mounjaro (tirzepatide), prescribed for weight loss; erectile-dysfunction treatment Cialis (tadalafil); Humalog, a rapid-acting insulin; and diabetes treatment Trulicity. Founded in 1876 by Civil War veteran Eli Lilly, it was the first to mass-produce insulin in the 1920s, one of the first to mass-produce penicillin during World War II, and an early producer of the polio vaccine. The company has also developed several major mental-health drugs, including Prozac (fluoxetine), one of the most widely prescribed selective serotonin reuptake inhibitors in the world. Eli Lilly operates in over 100 countries.

Paulo Nunes dos Santos—Bloomberg/Getty Images
- Company Information
- Future 50
- Best Companies To Work For Europe
- World's Most Admired Companies
- America's Most Innovative Companies
- Key Financials (last Fiscal Year)
- Profit Ratios
- Earnings Per Share (last Fiscal Year)
- Total Return
- Updated:7/28/26
- Country/Territory:U.S.
- Headquarters:Indianapolis
- Industry:Pharmaceuticals
- CEO:David A. Ricks
- Website:https://www.lilly.com
- Ticker:LLY
- Company type:Public
- Revenues ($M):$65,179
- Profits ($M):$20,640
- Market value ($M):$1,113,016
- Number of employees:50,000
Market value as of July 13, 2026.
- Overall Score:98.6
- Sector:Health Care
- Sector:Health Care
- CEO/Top executive:David A. Ricks
- Group headquarters:U.S.
- HQ location:U.S.
- GPTW national list:Italy, Spain, Turkey
- Woman CEO:no
- Number of Years on List:2
- Sector:Natural resources
- Industry:Pharmaceuticals
- Current All-Star Rank:16
- Previous All-Star Rank:21
- Industry Rank:1
- Previous Industry Rank:1
- Overall Score:8.09
- Innovation:1
- People Management:1
- Use of Corporate Assets:1
- Social Responsibility:5
- Quality of Management:1
- Financial Soundness:1
- Long-Term Investment Value:2
- Quality of Products/Services:1
- Global Competitiveness:5
- Sector:Health Care
- Strongest Dimension:Product innovation
- Years on list:1
- Previous rank:-
- State:Indiana
- $ Millions% change
- Revenues ($M):$65,17944.7%
- Profits ($M):$20,64094.9%
- Assets ($M):$112,476-
- Total Stockholder Equity ($M):$26,535-
- Profit as % of Revenues:31.7%
- Profits as % of Assets:18.4%
- Profits as % of Stockholder Equity:77.8%
- Earnings Per Share ($):23.00
- EPS % Change (from prior fiscal year):96%
- EPS % Change (5 year annual rate):27.6%
- EPS % Change (10 year annual rate):26.1%
- Total Return to Investors (last year):40.2%
- Total Return to Investors (5 year, annualized):46.3%
- Total Return to Investors (10 year, annualized):31.2%
Eli Lilly stock chart
Latest news on Eli Lilly
Eli Lilly in Fortune Rankings
- Fortune 500
- Fortune Global 500
- America's Most Innovative Companies
- World's Most Admired Companies
- Fortune 100 Best Companies To Work For – Europe
- The Future 50
- Fortune Sector Leaders: Health Care